Ionis Pharmaceuticals, Inc.
Modified compounds and uses thereof
Last updated:
Abstract:
The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
Status:
Grant
Type:
Utility
Filling date:
12 Feb 2019
Issue date:
17 May 2022